Skip Navigation

Annals of Oncology 2005 16(4):521-522; doi:10.1093/annonc/mdi130
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sobrero, A.
Right arrow Articles by Sciallero, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sobrero, A.
Right arrow Articles by Sciallero, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months?

A. Sobrero* and S. Sciallero

Medical Oncology, Ospedale San Martino and CBA, Genova, Italy

(* Email: alberto.sobrero@hsanmartino.liguria.it)

The first 10% of the full text of this article appears below.

The article by Chau et al. [1Go] on the adjuvant treatment of 801 stage II and III colorectal cancer patients demonstrates that 3 months of protracted venous infusion (PVI) 5-fluorouracil (5-FU) is as efficacious as 6 months of standard bolus 5-FU–leucovorin (LV) and that it is significantly less toxic. Although the study was designed as a superiority trial, the results allow us to conclude that the chances of the 3-month regimen being inferior to the 6-month treatment plan are extremely low (P <0.005).

 This article is an update and an extension of a previously published report on the first 716 patients [2Go] showing similar results at a much shorter follow-up time point: significantly lower toxicity of the infusional regimen and no difference in overall survival. That preliminary report also indicated that the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
D. J. Kerr
Concordia res parvae crescent
Ann. Onc., January 1, 2006; 17(1): 3 - 4.
[Full Text] [PDF]